Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have received an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company.

Several research analysts have issued reports on BAYRY shares. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd.

Bayer Aktiengesellschaft Stock Performance

BAYRY opened at $14.44 on Monday. Bayer Aktiengesellschaft has a 1-year low of $7.40 and a 1-year high of $15.23. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The company has a market cap of $56.75 billion, a P/E ratio of -28.31, a price-to-earnings-growth ratio of 4.52 and a beta of 0.55. The company has a fifty day moving average price of $12.64 and a two-hundred day moving average price of $12.13.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. The company had revenue of $12.53 billion for the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Analysts predict that Bayer Aktiengesellschaft will post 1.28 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.